Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Burning Rock Biotech (BNR) Net Margin (2019 - 2025)

Burning Rock Biotech has reported Net Margin over the past 7 years, most recently at 12.17% for Q4 2025.

  • For Q4 2025, Net Margin rose 5338.0% year-over-year to 12.17%; the TTM value through Dec 2025 reached 10.27%, up 5688.0%, while the annual FY2025 figure was 2.81%, 1320.0% up from the prior year.
  • Net Margin for Q4 2025 was 12.17% at Burning Rock Biotech, up from 12.74% in the prior quarter.
  • Over five years, Net Margin peaked at 6.53% in Q2 2025 and troughed at 200.36% in Q2 2022.
  • A 5-year average of 106.15% and a median of 131.98% in 2023 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: plummeted -5770bps in 2021 and later surged 11063bps in 2023.
  • Year by year, Net Margin stood at 170.44% in 2021, then rose by 11bps to 152.02% in 2022, then grew by 12bps to 133.97% in 2023, then skyrocketed by 51bps to 65.55% in 2024, then surged by 81bps to 12.17% in 2025.
  • Business Quant data shows Net Margin for BNR at 12.17% in Q4 2025, 12.74% in Q3 2025, and 6.53% in Q2 2025.